CARDIOME PHARMA CORP  

(Public, NASDAQ:CRME)   Watch this stock  
Find more results for Richard Rieder�
6.91
-0.19 (-2.68%)
Aug 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.83 - 7.02
52 week 2.04 - 11.00
Open 7.01
Vol / Avg. 0.00/60,824.00
Mkt cap 112.11M
P/E     -
Div/yield     -
EPS -1.28
Shares 16.52M
Beta 1.75
Inst. own 283%
Nov 4, 2014
Q3 2014 Cardiome Pharma Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 13, 2014
Cardiome Pharma Corp at Canaccord Genuity Growth Conference
Aug 11, 2014
Q2 2014 CARDIOME PHARMA CORP Earnings Release
Aug 11, 2014
Q2 2014 Cardiome Pharma Corp Earnings Call
Jun 25, 2014
Cardiome Pharma Corp at JMP Securities Healthcare Conference
Jun 18, 2014
Cardiome Pharma Corp at Bloom Burton & Co Healthcare Investor Conference
Jun 16, 2014
Cardiome Pharma Corp Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -55.30% 105.81%
Operating margin -52.26% 91.71%
EBITD margin - -295.88%
Return on average assets -34.66% 10.36%
Return on average equity -56.32% 31.30%
Employees 75 -
CDP Score - -

Address

6TH FLOOR, 6190 AGRONOMY RD.
VANCOUVER, BC V6T 1Z3
Canada
+1-604-6776905 (Phone)
+1-604-6776915 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cardiome Pharma Corp. (Cardiome) is a research-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of new therapies. It has one product, BRINAVESS, approved for marketing in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. The Company�s clinical programs are also focused on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. Cardiome also has several pre-clinical projects directed at various therapeutic indications. The Company operates primarily in one business segment with all of its assets located in Canada and operations located in Canada, the United States, Switzerland and the United Kingdom. In March 2012, the Company announced that Merck & Co., Inc. (Merck) discontinued further development of vernakalant (oral). In November 2013, Cardiome Pharma Corp. completed the acquisition of Correvio LLC.

Officers and directors

Robert W. Rieder Chairman of the Board
Bio & Compensation  - Reuters
William L. Hunter M.D. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Jennifer Archibald Chief Financial Officer
Bio & Compensation  - Reuters
Sheila M. Grant Chief Operating Officer
Bio & Compensation  - Reuters
Karim Lalji Chief Commercial Officer
Bio & Compensation  - Reuters
Richard M. Glickman Lead Independent Director
Bio & Compensation  - Reuters
W. James O'Shea Director
Bio & Compensation  - Reuters
Peter W. Roberts CPA Independent Director
Bio & Compensation  - Reuters
Harold H. Shlevin M.D., Ph.D., Independent Director
Age: 63
Bio & Compensation  - Reuters